Gary E. Schiltz
Northwestern University
77 Papers
124 Citations
Gary E. Schiltz is an academic researcher from Northwestern University. The author has contributed to research in topics: Chemistry & Biology. The author has an hindex of 15, co-authored 54 publications. Previous affiliations of Gary E. Schiltz include Purdue University & University of Illinois at Chicago.
Chat about Author
Papers
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han,Atul D. Jain,Mihai I. Truica,Javier Izquierdo-Ferrer,Jonathan F. Anker,Barbara Lysy,Vinay Sagar,Yi Luan,Zachary R. Chalmers,Kenji Unno,Hanlin Mok,Rajita Vatapalli,Young Yoo,Yara Rodriguez,Irawati Kandela,J. Brandon Parker,Debabrata Chakravarti,Rama K. Mishra,Gary E. Schiltz,Sarki A. Abdulkadir +19 more
TL;DR: A series of small-molecule MYC inhibitors that engage MYC inside cells, disrupt MYC/MAX dimers, and impair MYC-driven gene expression are developed that enhance MYC phosphorylation on threonine-58, consequently increasing proteasome-mediated MYC degradation.
363
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation
Andrea E. Calvert,Alexandra Chalastanis,Yongfei Wu,Lisa A. Hurley,Fotini M. Kouri,Yingtao Bi,Maureen Kachman,Jasmine L. May,Elizabeth T. Bartom,Youjia Hua,Rama K. Mishra,Gary E. Schiltz,Oleksii Dubrovskyi,Andrew P. Mazar,Marcus E. Peter,Hongwu Zheng,C. David James,Charles F. Burant,Navdeep S. Chandel,Ramana V. Davuluri,Craig Horbinski,Alexander H. Stegh +21 more
TL;DR: It is suggested that IDH1 upregulation represents a common metabolic adaptation by GBMs to support macromolecular synthesis, aggressive growth, and therapy resistance.
189
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Lijie Zhai,April Bell,Erik Ladomersky,Kristen L. Lauing,Lakshmi Reddy Bollu,Jeffrey A. Sosman,Bin Zhang,Jennifer D. Wu,Stephen D. Miller,Joshua J. Meeks,Rimas V. Lukas,Eugene Wyatt,Lynn Doglio,Gary E. Schiltz,Robert H. McCusker,Derek A. Wainwright +15 more
TL;DR: This work converges on the central premise that maximal immunotherapeutic efficacy in subjects with advanced cancer requires both IDO enzyme- and non-enzyme-neutralization, which is not adequately addressed by available IDO-targeting pharmacologic approaches at this time.
Syntheses of FDA Approved HIV Protease Inhibitors.
TL;DR: This review focuses on the published syntheses of currently FDA approved HIV protease inhibitor drugs, their isosteres and ligands.
Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy
Kaiwei Liang,Edwin R. Smith,Yuki Aoi,Kristen L. Stoltz,Hiroaki Katagi,Ashley R. Woodfin,Emily J. Rendleman,Stacy A. Marshall,David C. Murray,Lu Wang,Patrick A. Ozark,Rama K. Mishra,Rintaro Hashizume,Gary E. Schiltz,Ali Shilatifard +14 more
TL;DR: In this article, peptidomimetic lead compounds, KL-1 and its structural homolog KL-2, are identified, which disrupt the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of RNA polymerase II (Pol II) from promoter-proximal pause sites and a reduced average rate of processive transcription elongation.
115